Opinion|Videos|November 20, 2026 (Updated: November 18, 2026)

Explaining First-Line Options to Patients With EGFR-Mutated NSCLC

Lyudmila Bazhenova, MD, of University of California San Diego Moores Cancer Center, says the first-line conversation in EGFR-mutated non–small cell lung cancer (NSCLC) was simple when every patient with an exon 19 deletion or L858R mutation received osimertinib. With 3 options that have very different adverse effect profiles, she says visits now take longer.

Lyudmila Bazhenova, MD, of University of California San Diego Moores Cancer Center, says the first-line conversation in EGFR-mutated non–small cell lung cancer (NSCLC) was simple when every patient with an exon 19 deletion or L858R mutation received osimertinib. With 3 options that have very different adverse effect profiles, she says visits now take longer. Edward S. Kim, MD, MBA, of City of Hope Orange County, says he starts with the broad picture: some treatments are single agents, some are combinations, and the combinations differ in adverse effects and schedules. He tries to use a combination because of better efficacy, but notes that not every patient can handle the added toxicity. Dr Bazhenova also leans toward combinations because of the survival benefit, and most of her patients receive osimertinib plus chemotherapy. She tells patients the chemotherapy can be stopped after 1 or 2 cycles if it affects their quality of life.


Related to this article